Asthma and COPD Drugs Market Analysis
The global asthma and COPD drugs market size is expected to exhibit a strong 7.90% CAGR over the forecast period from 2019 to 2025, according to the latest research report from Market Research Future (MRFR). The global asthma and COPD drugs market is expected to reach a valuation of USD 43.4 billion by 2025, driven by the growing demand for asthma and COPD drugs and the growing prevalence of asthma and COPD.
The growing prevalence of asthma and COPD is the major driver for the global asthma and COPD drugs market. Asthma is an inflammatory condition that affects the lungs and makes breathing difficult. COPD is an umbrella term for a number of pulmonary conditions that result in damage to the lung tissue and difficulty in breathing. Diseases such as emphysema and chronic bronchitis also fall under the umbrella term of COPD.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8749
The growing air pollution around the world has led to a growing prevalence of asthma and COPD in the recent past. In recent years, urban areas around the world have grown at a rapid rate, leading to more purchasing of vehicles, as well as increasing construction of factories and other plants that spew toxic chemicals into the air. This has been a major driver for the prevalence of asthma, as asthma is usually triggered by environmental factors such as dust and pollutants. The growing presence of pollutants in the air, especially in urban areas, is likely to be a major driver for the global asthma and COPD drugs market over the forecast period.
The increasing popularity of smoking is also responsible for the growing prevalence of asthma and COPD. Smoking affects the lungs adversely, in that it affects the lungs’ capacity to process and filter air and damages lung tissue. This leads to various forms of COPD, leading to a growing demand for asthma and COPD drugs over the last few years. This is likely to remain a major driver for the global asthma and COPD drugs market over the forecast period.
Asthma and COPD Drugs Market Competitive Landscape:
Leading players in the global asthma and COPD drugs market include Chiesi Farmaceutici SpA, Boehringer Ingelheim International GmbH, AstraZeneca, and GSK plc.
In April 2019, Boehringer Ingelheim invested USD 117.46 million (EUR 105 million) for expanding its production sites in Dortmund and Ingelheim for the manufacturing of its respiratory products
In August 2018, The European Commission approved Nucala (mepolizumab) for the treatment of pediatric patients who have severe eosinophilic asthma in the European region. This approval will help to meet the high unmet need of the European population, as the severity of the disease is high among the children and adolescents compared to adults in the region.
Asthma and COPD Drugs Market Segmentation:
The global asthma and COPD drugs market has been segmented on the basis of disease, product, route of administration, distribution channel, and region.
By disease, the global asthma and COPD drugs market is bifurcated into asthma and COPD.
By product, the global asthma and COPD drugs market has been segregated into long-term asthma control medications and quick-relief medications. The long-term asthma control medications are further segmented into combination drugs, anticholinergics, inhaled corticosteroids, long-acting beta-agonists, theophylline, and others. The combination drugs segment is further segregated into Seretide/Advair, Symbicort, Relvar/Breo Ellipta, Flutiform, Dulera, and Others. Anticholinergics are further sub-segmented into Spiriva and others. Inhaled corticosteroids are further segmented into Pulmicort, Flovent, Qvar, and others. The quick-relief medications have been further segmented into short-acting beta-agonists, oral & intravenous corticosteroids, ipratropium bromide (Atrovent), and others. Short-acting beta-agonists have been further segregated into Proair and Ventolin.
By route of administration, the global asthma and COPD drugs market is segmented into oral, inhaled, and others.
By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment holds a dominant share in the global asthma and COPD drugs market and is likely to remain the leading revenue generator over the forecast period.
Asthma and COPD Drugs Market Regional Outlook:
The Americas are likely to dominate the global asthma and COPD drugs market, followed by Europe. Asia Pacific is the third largest regional market for asthma and COPD drugs and is likely to exhibit the fastest growth over the forecast period.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/asthma-copd-drugs-market-8749
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/asthma-copd-drugs-market-8749